Genentech Signs an Agreement with Nimble to Discover and Develop Novel Peptide-Based Therapies

 Genentech Signs an Agreement with Nimble to Discover and Develop Novel Peptide-Based Therapies

Genentech Signs an Agreement with Nimble to Discover and Develop Novel Peptide-Based Therapies

Shots:

  • Nimble to receive up front, milestones & royalties on sales of the therapies developed under the collaboration. The collaboration will accelerate the discovery of novel therapies targeting multiple diseases
  • The agreement will utilize Nimble’s peptide synthesis, screening & optimization platform, chemical diversity, and integrated suite of assays enabling the discovery & optimization of compounds for intracellular and extracellular targets
  • The collaboration will merge the strength of both the companies to offer new therapies to the patients

Click here ­to­ read full press release/ article | Ref: FDA | Image: Life Science PR Review

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post